Massachusetts Webinar: Why Aren't We Preventing the Preventable: Updates in Meningococcal B and Other Vaccine Hot Topics

Activity Details
  • Credit Type: CME
  • Credit Amount: 1.00
  • Cost: Free
  • Release: Dec 19, 2016
  • Expires: Mar 1, 2017
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Missed the Webinar? There's Still Time to Participate and Obtain CME Credit! 

Please Note: We are unable to offer AAP Credit for the archived version.

 

 

 

Faculty

Gary  S.  Marshall Gary S. Marshall, MD
Professor of Pediatrics,
Chief, Division of Pediatric Infectious Diseases
University of Louisville School of Medicine
Louisville, KY

Stephen I.  Pelton Stephen I. Pelton, MD
Professor of Pediatrics - Boston University School of Medicine
Professor of Epidemiology - Boston University School of Public Health
Director, Section of Pediatric Infectious Diseases - Boston Medical Center

Amanda Smith Amanda Smith, MD
Course Co-Director
Internal Medicine/Pediatrics
KentuckyOne Primary Care Associates
Lexington, KY

Needs Statement

Meningococcal disease, specifically serotype B (MnB), is an ongoing problem in this country, particularly in light of recent university outbreaks. The disease can develop from initial symptoms to death within 24 hours, and as many as 20% of survivors have permanent sequelae. Notably, incidence rates are often a misconception due to under-detection and under-reporting. Given how disabling diseases can be that could have been prevented with vaccination, it is essential that healthcare workers delivering vaccinations enhance their standards of care in practice in order to deliver the highest rates of preventative care. The goal of the activity is to improve comprehension and initiate practice changes so as to improve immunization rates for all patients who are currently scheduled for the MnB vaccination.

 

Target Audience

The target audience includes pediatricians, primary care physicians, OB-GYNs, infectious disease specialists and other clinicians who care for patients who are scheduled to receive the Meningococcal B vaccine.

 

Objectives

At the conclusion of this activity, participants will better able to:

1. Discuss the epidemiology of MnB in the United States and the profiles of patients at greatest risk for this vaccine-preventable disease.

2. Describe recent 2015 MnB immunization updates made by the Advisory Committee on Immunization Practices (ACIP) and the rationale behind a category B recommendation.

3. Examine the mechanism of action, contraindications, and adverse effect profiles of current MnB vaccines.

4. Given a patient case, discuss practice considerations for administering the MnB vaccine such as documentation, billing, and screening for additional immunizations.

5. Recognize and respond to the opportunity to counsel and screen expectant mothers for recommended immunizations. 

 

Accreditation

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRACategory 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAP Accreditation:
FOR THIS RECORDING WE'RE UNABLE TO PROVIDE AAP ACCREDITATION

 

 

Faculty Disclosure

Disclosure Policy:
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. 

Disclosures:
Dr. Pelton receives Grant/Research/Clinical Trial Support from Pfizer; Merck and Cempra. He is a Consultant for Pfizer, GSK, Sanofi and Sequiris.
Dr. Marshall is on the advisory board and an invesitagor for GSK, Merck, Novartis, Pfizer and Seqirus. He is a speaker for Pfizer and Sanofi.

Planning Committee Disclosures:
Elizabeth Drury, Dana Frazier, and Julie White, planning committee members, have no relevant relationships to disclose. Allison Smith, MD, reviewer, Carol Moloney, RN MSN CPNP, CNE Course Advisor have no relevant relationships to disclose.
Lee Wetzler, MD, content contributor, is an advisor for GSK.
Sheldon Kaplan, MD, faculty, receives grant/research/clinical trial support from Pfizer, Cubist, Forest Lab. He is a consultant/Advisory Boards for Pfizer and Theravance.

Acknowledgment:
This program is supported by an educational grant from GlaxoSmithKline.

 

 

Disclaimer:

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.